Business
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validat...
About this update from Caprock Mining Corp
[{"type":"text","content":"Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel\n\n\n\n\n –Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development–\n \n\n\n SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) --\n \n Capricor Therapeutics, Inc\n \n . (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapies for rare diseases, today announced the publication in\n \n Biomedicines\n \n , an international peer-reviewed journal, describing a novel in-vitro potency assay designed to characterize the anti-fibrotic mechanism of action of the Capricor’s lead investigational product, Deramiocel, which is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD).\n \n\n The publication, titled\n \n “A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel\n \n ,” showed results that further elucidate the biological activity of cardiosphere-derived cells (CDCs), the active component of Deramiocel. The study found that CDCs, through their secreted exosomes and soluble factors, suppressed collagen I and III gene expression in primary human fibroblasts in vitro, supporting their potential to modulate fibrotic processes associated with disease progression.\n \n\n Findings were consistent across more than one hundred Deramiocel manufacturing lots, demonstrating the anti-fibrotic mechanism of action, which aligns with in vivo pharmacodynamic studies and more than four years of clinical data demonstrating stabilization of cardiac function in DMD patients. The assay was developed and validated as a tool to help assess Deramiocel’s lot-to-lot bioactivity and potency under quality-controlled manufacturing conditions, enhancing Capricor’s ability to ensure product consistency and quality as development progresses.\n \n\n “This publication contributes to the growing body of evidence describing how cardiosphere-derived cells may modulate fibrotic and inflammatory pathways that underlie the progression of Duchenne muscular dystrophy,” said Linda Marbán, Ph.D., Chief Executive Off...